A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
Dr. Nabil Saba shares the first evidence-based guideline on thyroid cancer from ASCO. He highlights recommendations on first- and subsequent-line systemic treatment – including multikinase inhibitors ...
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
Origin in C cells renders disease calcitonin/CEA-secreting and non–iodine-avid, eliminating therapeutic utility of radioactive iodine and emphasizing early, definitive management. Clinical phenotypes ...
Thyroid cancer is often a highly treatable disease. Most cases are detected in early stages and have excellent outcomes. There are several different types of thyroid cancer, and recent changes in ...
A new review in the Journal of Translational Medicine shows how combining molecular imaging, genomic profiling, and ...
Thyroid cancer often carries far less fear in medical circles than it does among patients, largely because, when detected early, it is among the most treatable cancers. The thyroid gland, a small ...
ROCHESTER, Minn. — Mayo Clinic researchers have identified a strategy that could help chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, overcome a major barrier to treating solid tumors ...
Papillary thyroid cancer staging depends on age, with stage 2 involving distant spread in younger patients and larger tumors or regional spread in older patients. Diagnosis involves physical exams, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results